Alissafi Lab

Research focus

ERC Starting Grant · 2020

A multi-parametric Regulatory T cell Atlas in cancer to predict immunotherapy response, adverse autoimmune events and to identify novel therapeutic targets

The advent of immune checkpoint inhibitors (ICI), that target regulatory pathways in T cells to unleash antitumor immune responses, has revolutionized cancer immunotherapy. However, despite the enormous success of ICI in the treatment of cancer, a significant proportion of patients do not respond, while responses are frequently accompanied by life-threatening autoimmune related adverse events (irAEs). Predictive biomarkers of clinical responses and new therapeutic strategies to harness anti-tumor immunity, while keeping autoimmunity in check represent a currently unmet need. Tregs, are an ideal candidate, since they are physiologically engaged in maintenance of self-tolerance, are the…

From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.